Nanomix Incorporated has announced the publication of an article in the January 24th issue of the Proceeding of National Academy of Sciences: http://www.pnas.org/cgi/content/full/103/4/921.
The paper reports the detection of single base genetic mutations on the company's carbon nanotube platform. The label-free electronic detection of DNA offers significant advantages for rapid point of care assays.
"This research further demonstrates the strength of the Sensation(TM) platform for bio molecule detection," said David Macdonald, President and CEO of Nanomix. "Feasibility has been established for a range of commercial opportunities related to detection of DNA, RNA, glucose, virus, and protein bio molecules. We are committed to collaboration with industry leaders to leverage features of the Sensation(TM) platform in valuable life science detection applications."
"Developed here at Nanomix, our proprietary platform enables small, automated handheld devices that allow point-of-care detection of bio molecules. This moves testing from clinical laboratories to the bedside, making it faster, simpler and less expensive," said Dr. Christian Valcke, Vice President of Research and Development at Nanomix. Dr. Valcke further stated "our expertise with nanoelectronic devices is backed by an extensive patent pipeline and represents a fundamentally new and advantageous approach to bio molecule detection."
http://www.nano.com
Posted 7th February 2006
